1. Home
  2. ADUS vs IMCR Comparison

ADUS vs IMCR Comparison

Compare ADUS & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Addus HomeCare Corporation

ADUS

Addus HomeCare Corporation

HOLD

Current Price

$93.00

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

IMCR

Immunocore Holdings plc

HOLD

Current Price

$28.57

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADUS
IMCR
Founded
1979
2008
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Medical/Nursing Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.4B
IPO Year
2009
2016

Fundamental Metrics

Financial Performance
Metric
ADUS
IMCR
Price
$93.00
$28.57
Analyst Decision
Buy
Buy
Analyst Count
9
10
Target Price
$133.78
$66.33
AVG Volume (30 Days)
186.5K
395.8K
Earning Date
05-04-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
23.40
30.39
EPS
1.36
0.25
Revenue
N/A
$249,428,000.00
Revenue This Year
$9.17
$14.57
Revenue Next Year
$4.70
$8.21
P/E Ratio
$68.51
$111.60
Revenue Growth
N/A
43.05
52 Week Low
$87.95
$27.56
52 Week High
$124.44
$40.71

Technical Indicators

Market Signals
Indicator
ADUS
IMCR
Relative Strength Index (RSI) 49.73 46.34
Support Level $89.99 $28.09
Resistance Level $96.54 $31.11
Average True Range (ATR) 2.55 1.31
MACD 0.30 -0.04
Stochastic Oscillator 55.36 31.30

Price Performance

Historical Comparison
ADUS
IMCR

About ADUS Addus HomeCare Corporation

Addus HomeCare Corp is engaged in the provision of in-home care services. The Company has three reportable segments: Personal Care, Hospice, and Home Health. The Personal Care segment provides non-medical assistance with activities of daily living, mainly to the elderly, chronically ill, and disabled individuals. The Hospice segment provides physical, emotional, and spiritual care for terminally ill patients and their families. The Home Health segment provides medical services to individuals requiring care during illness or recovery. It generates the majority of its revenue from the Personal Care segment.

About IMCR Immunocore Holdings plc

Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.

Share on Social Networks: